Drug intelligence / Profile preview

MEM-PD119

Development stage: Preclinical
Lead developer: Gb Sciences
Modality: Small Molecules

Overview

MEM-PD119 is a chemical drug under preclinical development, originally developed by GB Sciences. It is being investigated primarily for the treatment of nervous system diseases, with a particular focus on Parkinson's disease. The drug also has potential applications in endocrinology and metabolic diseases. As of the latest updates, its highest research and development status is preclinical, and no detailed mechanism of action or molecular target has been publicly disclosed.

Other names: MEM.PD119

Beyond the preview

Go deeper on MEM-PD119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEM-PD119.

Explore the full profile